Building Manufacturing Capabilities for Next-Generation Medicines

The pharmaceutical industry stands at a critical inflection point where strategic manufacturing decisions made today will determine competitive positioning for the next decade. As therapeutic modalities grow more sophisticated—from cell and gene therapies to mRNA platforms and complex biologics—manufacturers must fundamentally rethink how they build, operate, and scale production networks. The challenge extends beyond incremental improvement: it requires simultaneous investment in future capabilities while maintaining excellence in current operations, all within an increasingly complex regulatory and supply chain environment. This session explores three fundamental imperatives shaping the future of biomanufacturing operations.